| Customization: | Available |
|---|---|
| CAS No.: | 258818-34-7 |
| Formula: | C32h55n9o10 |
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Appearance: White Crystalline Lyophilized Powder
Package: 1mg,2mg,5mg.10mg
Shelf Life :24Months
Storage:Refrigeration keep dry and away from light.
It is a novel, once weekly, dual GIP/GLP-1 receptor agonist and is under development for the treatment of type 2 diabetes (T2D) and obesity.
It is a dual glucose-dependent insulinotropic polypeptide-GLP-1 receptor agonist. Its structure is primarily based on the glucose-dependent insulinotropic polypeptide amino acid sequence and includes a C20 fatty diacid moiety. Its half-life of approximately 5 days allows once-weekly subcutaneous administration. A phase 2b trial involving patients with type 2 diabetes showed that those who received had dose-dependent reductions in the glycated hemoglobin level and weight at 26 weeks.
Once-weekly injectable a selective GLP-1 receptor agonist, is approved for the treatment of type 2 diabetes at doses up to 1 mg. In trials involving patients who received sema glutide, the mean reductions in the glycated hemoglobin level have been reported to be as high as 1.8 percentage points and the mean reductions in body weight have been reported to be as high as 6.5 kg.
We conducted the SURPASS-2 trial (A Study of [LY3298176] versus Once Weekly as Add-on Therapy to Metformin in Participants with Type 2 Diabetes) to compare the efficacy and safety of tir zepatide at doses of 5 mg, 10 mg, and 15 mg with those of sema glutide at a dose of 1 mg in patients with type 2 diabetes that had been inadequately controlled with metformin monotherapy
Function:
1.Diabetes Type 2 Medicine
2.Oral GLP-1RA Medication
3.Weight Loss
4.Diabetes Mellitus
5.Obesity
6.Diabetic Coma (in DM Type II)
7.Diabetic Ketoacidosis (in DM Type II)
8. Cardiovascular Risk Reduction
){kind=link}